Variant Creutzfeldt-Jakob Disease

Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders: Second Edition

Volumn , Issue , 2011, Pages 354-363

  Ironside, James W ^a   Head, Mark W ^a   Will, Robert G ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Biochemistry; Blood transfusion; Bovine spongiform encephalopathy; BSE; Epidemiology; Florid plaque; MRI; Neuropathology; Prevalence; Prion protein; Variant creutzfeldt Jakob disease; VCJD

Indexed keywords

EID: 84860338856     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444341256.ch36     Document Type: Chapter

References (53)

1. Will RG, Ironside JW, Zeidler M et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-925.
2. Kaski D, Mead S, Hyare H et al. Variant CJD in an individual heterozygous for PRNP codon 129. Lancet 2010; 374: 2128.
3. Bateman D, Hilton D, Love S, Zeidler M, Beck J, Collinge J. Sporadic Creutzfeldt-Jakob disease in a 18-year old in the UK. Lancet 1995; 346: 1155-1156.
4. Britton TC, Al-Saraj S, Shaw C, Campbell T, Collinge J. Sporadic Creutzfeldt-Jakob disease in a 16-year old in the UK. Lancet 1995; 346: 1155.
5. World Health Organization. Report of a WHO consultation on clinical and neuropathological characteristics of the new variant of CJD and other human and animal transmissible spongiform encephalopathies. Geneva: World Health Organization, 1996.
6. Molesworth AM, Cousens SN, Gill ON, Ward HJT. Variant Creutzfeldt-Jakob disease: a country-wide or local risk? J Epidemiol Commun Health 2010; 64 (7): 616-621.
7. Smith PG, Cousens SN, Huillard d'Aignaux JN, Ward HJT, Will RG. The epidemiology of variant Creutzfeldt-Jakob disease. Curr Top Microbiol Immunol 2004; 284: 161-191.
8. Ward HJT, Everington D, Cousens SN et al. Risk factors for variant Creutzfeldt-Jakob disease: a case-control study. Ann Neurol 2006; 59: 111-120.
9. Hill AF, Butterworth RJ, Joiner S et al. The same prion strain causes vCJD and BSE. Nature 1997; 389: 183-189.
10. Bruce ME, Will RG, Ironside JW et al. Transmissions to mice indicate that "new variant" CJD is caused by the BSE agent. Nature 1997; 389: 498-501.
11. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiology Review study. Vox Sang 2006; 91: 221-230.
12. Health Protection Agency. Fourth case of transfusion-associated variant-CJD. Health Protect Rep 2007; 1: 3.
13. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364: 527-529.
14. Peden A, McCardle L, Head MW et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010: 16(2): 296-304.
15. Will RG, Zeidler M, Stewart GE et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol 2000; 47: 575-582.
16. Mead S, Poulter M, Uphill J et al. Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol 2009; 8: 57-66.
17. Zeidler M, Johnstone EC, Bamber RW et al. New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet 1997; 350: 908-910.
18. Summers DM, Collie DA, Zeidler M, Will RG. The pulvinar sign in variant Creutzfeldt-Jakob disease. Arch Neurol 2004; 61: 446-447.
19. National Creutzfeldt-Jakob Disease Surveillance Unit. Diagnostic criteria for Creutzfeldt-Jakob disease. www.cjd.ed.ac.uk.
20. Zeidler M, Sellar RJ, Collie DA et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 2000; 355: 1412-1418.
21. De Silva R, Patterson J, Hadley D, Russell A, Turner M, Zeidler M. Single photon emission computed tomography in the identification of new variant Creutzfeldt-Jakob disease: case reports. BMJ, 1998; 31: 593-594.
22. Yamada M, Variant CJD Working Group, Creutzfeldt-Jakob Disease Surveillance Committee, Japan. The first Japanese case of variant Creutzfeldt-Jakob disease showing periodic electroencephalogram. Lancet 2006; 367: 874.
23. Binelli S, Agazzi P, Giaccone G et al. Periodic electroencephalogram complexes in a patient with variant Creutzfeldt-Jakob disease. Ann Neurol 2006; 59: 423-427.
24. Sanchez-Juan P, Green A, Ladogana N et al. CSF test in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2006; 67: 637-643.
25. Ironside JW, McCardle L, Horsburgh A, Lim Z, Head MW. Pathological diagnosis of variant Creutzfeldt-Jakob disease. APMIS 2002; 110: 79-87.
26. Shimizu S, Hoshi K, Muramoto T et al. Creutzfeldt-Jakob disease with florid-type plaques after cadaveric dura mater grafting. Arch Neurol 1999; 56: 357-363.
27. Sikorska B, Liberski PP, Sobow T, Budka H, Ironside JW. Ultrastructural study of florid plaques in variant Creutzfeldt-Jakob disease: a comparison with amyloid plaques in kuru, sporadic Creutzfeldt-Jakob disease and Gerstmann-Straussler-Scheinker disease. Neuropathol Appl Neurobiol 2009; 35: 46-59.
28. Grigoriev V, Escaig-Haye F, Streichenberger N et al. Submicroscopic immunodetection of PrP in the brain of a patient with a new variant of Creutzfeldt-Jakob disease. Neurosci Lett 1999; 264: 57-60.
29. Head MW, Northcott V, Rennison K et al. Prion protein accumulation in eyes of patients with sporadic and variant CJD. Invest Ophthalmol Vis Sci 2003; 44: 342-346.
30. Head MW, Ritchie D, Smith N et al. Peripheral tissue involvement in sporadic, iatrogenic and variant Creutzfeldt-Jakob disease: an immunocytochemical, quantitative and biochemical study. Am J Pathol 2004; 164: 143-153.
31. Peden AH, Ritchie DL, Uddin HP et al. Abnormal prion protein in the pituitary in sporadic and variant Creutzfeldt-Jakob disease. J Gen Virol 2007; 88: 1068-1072.
32. Peden AH, Ritchie DL, Head MW, Ironside JW. Detection and localization of PrPSc in the skeletal muscle of patients with variant, iatrogenic and sporadic forms of Creutzfeldt-Jakob disease. Am J Pathol 2006; 168: 927-935.
33. Bruce ME, McConnell I, Will RG, Ironside JW. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 2001; 358: 164-165.
34. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95: 13363-13383.
35. Head MW, Bunn TJ, Bishop MT et al. Prion protein heterogeneity in sporadic but not variant Creutzfeldt-Jakob disease: UK cases 1991-2002. Ann Neurol 2004; 55: 851-859.
36. Parchi P, Zou W, Wang W et al. Genetic influence on the structural variation of the abnormal prion protein. Proc Natl Acad Sci USA 2000; 97: 10168-10172.
37. Brandel JP, Heath CA, Head MW et al. Variant Creutzfeldt-Jakob disease in France and the United Kingdom: evidence for the same strain of agent. Ann Neurol 2009; 65: 249-256.
38. Head MW, Tissingh G, Uitdehaag BM et al. Sporadic Creutzfeldt-Jakob disease in a young Dutch valine homozygote: atypical molecular phenotype. Ann Neurol 2001; 50: 258-261.
39. Polymenidou M, Stoeck K, Glatzel M, Vey M, Aguzzi A. Coexistence of multiple PrP Sc types in individuals with Creutzfeldt-Jakob disease. Lancet Neurol 2005; 4: 805-814.
40. Yull HM, Ritchie DL, Langeveld JPM et al. Detection of type 1 prion protein in variant Creutzfeldt-Jakob disease. Am J Pathol 2006; 168: 151-157.
41. Hill AF, Butterworth RJ, Joiner S et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy specimens. Lancet 1999; 353: 183-189.
42. Ritchie DL, Boyle A, McConnell I, Head MW, Ironside JW, Bruce ME. Transmission of variant Creutzfeldt-Jakob disease brain and lymphoreticular tissue show uniform and conserved BSE-related phenotypic properties on primary and secondary passage in wild-type mice. J Gen Virol 2009; 90: 3075-3082.
43. Bishop, MT, Hart P, Aitchison L et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol 2006; 5: 393-398.
44. Jones M, Wight D, Barron R et al. Molecular model of prion transmission to humans. Emerg Infect Dis 2009; 15: 2013-2016.
45. McLean CA, Ironside JW, Alpers MP et al. Comparative neuropathology of Kuru and the new variant of Creutzfeldt-Jakob disease: evidence for the strain of agent over genotype of host. Brain Pathol 1998; 8: 429-437.
46. Head MW, Yull HM, Ritchie DL, Bishop MT, Ironside JW. Pathological investigation of the first blood donor and recipient pair linked by transfusion-associated variant Creutzfeldt-Jakob disease transmission. Neuropathol Appl Neurobiol 2009; 35: 433-436.
47. Hilton DA, Ghani AC, Conyers L et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004; 203: 733-739.
48. Ironside JW, Bishop MT, Connolly K et al. Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ 2006; 332: 1186-1188.
49. Edgeworth JA, Farmer M, Sicilia A et al. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet 2011; 377: 487-493.
50. Turner ML, Ludlam CA. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol 2009; 145: 669-670.
51. Murray K, Peters J, Stellitano L, Winstone A, Verity C, Will R. Is there evidence of vertical transmission of variant Creutzfeldt-Jakob disease? J Neurol Neurosurg Psychiatry 2010; Jul 26 (epub ahead of print).
52. Collinge J, Gorham M, Hudson F et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009; 8: 334-344.
53. Bone I, Belton L, Walker AS, Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol 2008; 15: 458-464.